EDWARDS LIFESCIENCES CORPORATION Edwards Lifesciences Corporation Stock
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.89 USD | -1.14% |
|
-1.24% | +13.95% |
| 05-23 | Some of the biggest splits in Corporate America | RE |
| 05-22 | Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98 | MT |
| Sales 2024 * | 6.56B 8.94B | Sales 2025 * | 7.2B 9.82B | Capitalization | 52.36B 71.37B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.61B 2.2B | Net income 2025 * | 1.86B 2.54B | EV / Sales 2024 * | 7.72 x |
| Net cash position 2024 * | 1.7B 2.32B | Net cash position 2025 * | 2.84B 3.87B | EV / Sales 2025 * | 6.87 x |
| P/E ratio 2024 * |
32.9
x | P/E ratio 2025 * |
28.3
x | Employees | 19,800 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Edwards Lifesciences Corporation
More recommendations
More press releases
More news
| 1 day | -1.14% | ||
| 1 week | -1.24% | ||
| 1 month | +3.07% | ||
| 3 months | +1.96% | ||
| 6 months | +27.11% | ||
| Current year | +13.95% |
1 week
85.79
88.63
1 month
84.6791.94
Current year
71.6796.12
1 year
60.5796.12
3 years
60.57131.73
5 years
51.51131.73
10 years
13.02131.73
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 14-12-31 | |
Scott Ullem
DFI | Director of Finance/CFO | 57 | 13-12-31 |
Todd Brinton
CTO | Chief Tech/Sci/R&D Officer | - | 19-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leslie Heisz
BRD | Director/Board Member | 63 | 16-07-04 |
| Chairman | 67 | 14-11-12 | |
Steven Loranger
BRD | Director/Board Member | 72 | 16-03-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.46% | 42 M€ | -0.77% | - | |
| 2.34% | 17 M€ | +6.09% | - | |
| 2.13% | 6 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 86.89 | -1.14% | 4,619,581 |
| 24-05-30 | 87.89 | +0.99% | 2,343,408 |
| 24-05-29 | 87.03 | -0.01% | 2,065,712 |
| 24-05-28 | 87.04 | -1.07% | 2,592,054 |
Delayed Quote Nyse, May 31, 2024 at 04:00 pm
More quotes
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
2024-06-04
- William Blair Growth Stock Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
86.89
USD
Average target price
96.55
USD
Spread / Average Target
+11.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.95% | 52.36B | |
| +7.01% | 217B | |
| +11.01% | 190B | |
| +19.20% | 143B | |
| +30.79% | 111B | |
| +1.48% | 64.59B | |
| -0.16% | 48.45B | |
| -6.20% | 38.03B | |
| +0.91% | 35.6B | |
| +19.95% | 30.31B |
- Stock Market
- Equities
- EW Stock
